marketcaparena
Search

    TVTX

    Travere Therapeutics, Inc.

    Company overview

    Market capitalization
    $5.80B
    Employees
    497
    Latest publication
    2026-09-29
    About Travere Therapeutics, Inc.

    Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ3 20252025-09-30 · USDQ1 20242024-03-31 · USDQ2 20192019-06-30 · USDQ3 20172017-09-30 · USDQ2 20172017-06-30 · USDQ1 20172017-03-31 · USDQ1 20162016-03-31 · USD
    Total Revenue169,584,000USD164,859,000USD41,374,000USD44,707,000USD40,340,000USD38,800,000USD33,620,000USD29,008,000USD
    Cost Of Revenue2,174,000USD1,585,000USD1,504,000USD979,000USD925,000USD797,000USD709,000USD757,000USD
    Gross Profit167,410,000USD163,274,000USD39,870,000USD43,728,000USD39,415,000USD38,003,000USD32,911,000USD28,251,000USD
    Research Development60,283,000USD51,890,000USD114,625,000USD37,934,000USD19,610,000USD19,482,000USD20,860,000USD14,672,000USD
    Selling General Administrative96,112,000USD86,453,000USD64,223,000USD38,970,000USD24,852,000USD28,835,000USD23,115,000USD19,125,000USD
    Total Operating Expenses163,456,000USD138,343,000USD179,107,000USD76,904,000USD44,462,000USD48,317,000USD43,975,000USD33,797,000USD
    Operating Income3,954,000USD24,931,000USD-139,237,000USD-36,529,000USD-10,608,000USD-13,598,000USD-14,408,000USD-8,241,000USD
    Total Other Income Expense Net-38,955,000USD783,000USD3,470,000USD-5,456,000USD-8,409,000USD-4,840,000USD-2,090,000USD14,387,000USD
    Interest Income3,356,000USD3,047,000USD6,032,000USD—————
    Interest Expense2,134,000USD2,751,000USD2,800,000USD4,817,000USD660,000USD658,000USD132,000USD163,000USD
    Income Before Tax-35,001,000USD25,714,000USD-135,767,000USD-38,632,000USD-19,017,000USD-15,154,000USD-13,154,000USD6,146,000USD
    Income Tax Expense-204,000USD8,000USD191,000USD69,000USD-1,223,000USD-1,925,000USD-2,064,000USD-5,070,000USD
    Discontinued Operations0USD———————
    Net Income-34,797,000USD25,706,000USD-136,061,000USD-38,701,000USD-17,794,000USD-13,229,000USD-11,090,000USD11,216,000USD
    Net Income Applicable To Common Shares-34,797,000USD———————
    Net Interest Income—296,000USD3,232,000USD—————
    Tax Provision—8,000USD191,000USD—————
    Net Income From Continuing Ops—25,706,000USD-135,958,000USD—————
    Ebit—28,465,000USD-132,967,000USD-33,815,000USD-18,952,000USD-14,196,000USD-12,722,000USD-5,336,000USD
    Ebitda—44,253,000USD-123,087,000USD-28,974,000USD-14,337,000USD-9,759,000USD-8,438,000USD-1,445,000USD
    Depreciation And Amortization—15,788,000USD9,880,000USD4,841,000USD4,615,000USD4,437,000USD4,284,000USD3,891,000USD
    Reconciled Depreciation—15,788,000USD9,880,000USD4,841,000USD4,615,000USD4,437,000USD4,284,000USD3,891,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20142014-12-31 · USDFY 20132013-12-31 · USDFY 20122012-12-31 · USDFY 20112011-12-31 · USDFY 20102010-12-31 · USD
    Total Revenue28,203,205USD————
    Cost Of Revenue570,979USD————
    Gross Profit27,632,226USD————
    Research Development47,795,223USD7,084,009USD662,502USD——
    Selling General Administrative59,644,696USD16,888,064USD30,257,017USD12,825USD13,432USD
    Total Operating Expenses107,439,919USD23,972,073USD30,257,017USD12,825USD13,432USD
    Operating Income-79,807,693USD-23,972,073USD-30,235,187USD-12,825USD-18,266USD
    Interest Expense55,024,176USD19,504,978USD105,917USD2,000USD10,333USD
    Income Before Tax-113,397,610USD-33,747,734USD-30,343,856USD-14,825USD-18,266USD
    Income Tax Expense-2,459,748USD75,775USD2,752USD—-23,022USD
    Net Income-110,937,862USD-33,823,509USD-30,343,856USD-14,825USD-18,266USD
    Ebit-79,508,038USD-14,242,756USD-30,237,937USD-12,825USD-18,266USD
    Ebitda-74,107,000USD-14,026,763USD-30,113,052USD-12,825USD-18,266USD
    Depreciation And Amortization5,401,038USD215,993USD124,885USD——
    Total Other Income Expense Net-33,889,610USD-9,729,317USD-86,839USD-2,000USD-10,333USD
    Other Operating Expenses———12,825USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets799,360,000USD555,188,000USD605,191,000USD538,581,000USD555,309,000USD548,799,000USD594,125,000USD504,410,000USD
    Cash And Equivalents117,735,000USD———————
    Total Current Assets615,141,000USD392,681,000USD437,565,000USD371,110,000USD379,567,000USD374,171,000USD416,702,000USD324,740,000USD
    Other Current Assets37,493,000USD34,347,000USD27,460,000USD28,048,000USD17,222,000USD13,616,000USD12,685,000USD15,775,000USD
    Other Non Current Assets8,511,000USD———————
    Total Liabilities774,838,000USD———————
    Total Current Liabilities152,025,000USD125,437,000USD159,904,000USD135,074,000USD189,540,000USD182,457,000USD200,751,000USD190,038,000USD
    Other Current Liabilities2,100,000USD———————
    Other Non Current Liabilities12,071,000USD———————
    Total Stockholder Equity24,522,000USD98,728,000USD114,828,000USD73,564,000USD32,747,000USD32,823,000USD59,077,000USD-30,454,000USD
    Total Equity Including Noncontrolling Interest24,522,000USD———————
    Net Receivables80,636,000USD87,302,000USD81,434,000USD82,984,000USD38,718,000USD34,381,000USD27,116,000USD25,170,000USD
    Inventory40,049,000USD6,356,000USD5,875,000USD5,548,000USD4,090,000USD3,932,000USD6,200,000USD6,356,000USD
    Property Plant Equipment Net11,976,000USD13,295,000USD14,598,000USD15,784,000USD16,897,000USD18,049,000USD19,631,000USD21,824,000USD
    Intangible Assets131,518,000USD109,286,000USD113,115,000USD108,682,000USD104,854,000USD103,063,000USD103,221,000USD103,458,000USD
    Accounts Payable7,495,000USD12,912,000USD24,800,000USD18,225,000USD19,134,000USD15,374,000USD23,534,000USD23,195,000USD
    Short Term Debt6,163,000USD6,017,000USD5,875,000USD5,734,000USD74,433,000USD74,218,000USD74,083,000USD73,896,000USD
    Common Stock9,000USD9,000USD9,000USD9,000USD9,000USD9,000USD9,000USD8,000USD
    Retained Earnings-1,544,612,000USD-1,509,815,000USD-1,472,713,000USD-1,475,442,000USD-1,501,148,000USD-1,488,393,000USD-1,447,167,000USD-1,386,903,000USD
    Accumulated Other Comprehensive Income-1,117,000USD-1,062,000USD-1,189,000USD-1,054,000USD-812,000USD-843,000USD-80,000USD-1,016,000USD
    Total Liab—456,460,000USD490,363,000USD465,017,000USD522,562,000USD515,976,000USD535,048,000USD534,864,000USD
    Other Current Liab—106,508,000USD129,229,000USD111,115,000USD95,973,000USD92,865,000USD100,319,000USD89,148,000USD
    Capital Stock—9,000USD9,000USD9,000USD9,000USD9,000USD9,000USD8,000USD
    Good Will—800,000USD753,000USD800,000USD753,000USD753,000USD800,000USD747,000USD
    Other Assets—-48,000USD—-47,000USD——-47,000USD—
    Cash—78,362,000USD93,035,000USD110,930,000USD75,154,000USD61,897,000USD58,535,000USD36,409,000USD
    Cash And Short Term Investments—264,676,000USD322,796,000USD254,530,000USD319,537,000USD322,242,000USD370,701,000USD277,439,000USD
    Net Debt—249,300,000USD246,832,000USD218,819,000USD324,419,000USD338,566,000USD343,049,000USD366,025,000USD
    Short Long Term Debt Total—327,662,000USD339,867,000USD329,749,000USD399,573,000USD400,463,000USD401,584,000USD402,434,000USD
    Long Term Debt—312,079,000USD311,724,000USD311,370,000USD311,016,000USD310,663,000USD310,310,000USD309,957,000USD
    Short Term Investments—186,314,000USD229,761,000USD143,600,000USD244,383,000USD260,345,000USD312,166,000USD241,030,000USD
    Property Plant Equipment Gross—13,295,000USD24,696,000USD15,784,000USD16,897,000USD18,049,000USD28,386,000USD21,824,000USD
    Common Stock Shares Outstanding—91,868,862shares90,293,735shares102,618,560shares88,946,000shares88,356,000shares83,105,000shares77,779,379shares
    Non Current Assets Total—162,555,000USD167,626,000USD167,518,000USD175,742,000USD174,628,000USD177,423,000USD179,670,000USD
    Non Current Liabilities Total—331,023,000USD330,459,000USD329,943,000USD333,022,000USD333,519,000USD334,297,000USD344,826,000USD
    Non Current Liabilities Other—9,378,000USD7,601,000USD5,928,000USD7,882,000USD7,274,000USD6,796,000USD16,288,000USD
    Non Currrent Assets Other—39,174,000USD39,160,000USD42,252,000USD53,238,000USD52,763,000USD53,771,000USD53,641,000USD
    Net Working Capital—267,244,000USD277,661,000USD236,036,000USD190,027,000USD191,714,000USD215,951,000USD134,702,000USD
    Unclassified Non Current Liabilities—9,566,000USD11,134,000USD12,645,000USD14,124,000USD15,582,000USD17,191,000USD18,581,000USD
    Unclassified Equity—1,609,587,000USD1,588,712,000USD1,550,042,000USD1,534,689,000USD1,522,041,000USD1,506,306,000USD1,357,449,000USD
    Short Long Term Debt————68,838,000USD68,758,000USD68,678,000USD68,599,000USD
    Unclassified Current Liabilities————-68,838,000USD-68,758,000USD-68,678,000USD-68,599,000USD
    Current Deferred Revenue——————2,815,000USD3,799,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets605,191,000USD594,125,000USD788,913,000USD672,585,000USD776,633,000USD607,439,000USD604,800,000USD709,160,000USD
    Intangible Assets113,115,000USD103,221,000USD103,690,000USD96,320,000USD147,499,000USD153,189,000USD157,200,000USD186,691,000USD
    Other Current Assets28,760,000USD12,685,000USD19,335,000USD15,023,000USD6,718,000USD8,143,000USD6,410,000USD4,028,000USD
    Total Liab490,363,000USD535,048,000USD588,103,000USD629,734,000USD474,521,000USD396,226,000USD383,604,000USD390,907,000USD
    Total Stockholder Equity114,828,000USD59,077,000USD200,810,000USD42,851,000USD302,112,000USD211,213,000USD221,196,000USD318,253,000USD
    Other Current Liab129,229,000USD100,319,000USD124,228,000USD108,464,000USD88,768,000USD80,527,000USD66,222,000USD75,210,000USD
    Common Stock9,000USD9,000USD7,000USD6,000USD6,000USD5,000USD4,000USD4,000USD
    Capital Stock9,000USD9,000USD7,000USD6,000USD6,000USD5,000USD4,000USD4,000USD
    Retained Earnings-1,472,713,000USD-1,447,167,000USD-1,125,622,000USD-1,014,223,000USD-765,966,000USD-585,875,000USD-416,444,000USD-270,017,000USD
    Other Assets753,000USD——-47,000USD36,000USD7,814,000USD14,709,000USD7,709,000USD
    Cash93,035,000USD58,535,000USD58,176,000USD61,688,000USD165,753,000USD84,772,000USD62,436,000USD102,873,000USD
    Cash And Short Term Investments322,796,000USD370,701,000USD566,851,000USD450,245,000USD552,882,000USD361,589,000USD398,524,000USD471,541,000USD
    Total Current Assets437,565,000USD416,702,000USD616,775,000USD486,437,000USD582,827,000USD410,407,000USD429,064,000USD495,678,000USD
    Total Current Liabilities159,904,000USD200,751,000USD177,908,000USD142,163,000USD124,088,000USD92,660,000USD95,449,000USD104,621,000USD
    Net Debt235,698,000USD343,049,000USD346,608,000USD345,800,000USD96,233,000USD130,567,000USD152,432,000USD114,675,000USD
    Short Term Debt5,875,000USD74,083,000USD4,909,000USD4,433,000USD3,908,000USD357,000USD2,613,000USD22,457,000USD
    Short Long Term Debt Total328,733,000USD401,584,000USD404,784,000USD407,488,000USD261,986,000USD215,696,000USD214,868,000USD217,548,000USD
    Long Term Debt311,724,000USD310,310,000USD377,263,000USD375,545,000USD226,581,000USD215,339,000USD204,861,000USD195,091,000USD
    Short Term Investments229,761,000USD312,166,000USD508,675,000USD388,557,000USD387,129,000USD276,817,000USD336,088,000USD368,668,000USD
    Net Receivables80,134,000USD27,116,000USD21,179,000USD16,646,000USD15,914,000USD33,067,000USD18,048,000USD14,490,000USD
    Inventory5,875,000USD6,200,000USD9,410,000USD4,523,000USD7,313,000USD7,608,000USD6,082,000USD5,619,000USD
    Accounts Payable24,800,000USD23,534,000USD41,675,000USD17,290,000USD15,144,000USD12,133,000USD26,614,000USD6,954,000USD
    Property Plant Equipment Net14,598,000USD19,631,000USD25,540,000USD30,049,000USD34,302,000USD9,418,000USD9,886,000USD3,146,000USD
    Property Plant Equipment Gross24,696,000USD28,386,000USD32,983,000USD30,049,000USD34,302,000USD9,418,000USD2,891,000USD3,146,000USD
    Accumulated Other Comprehensive Income-1,189,000USD-80,000USD-1,456,000USD-2,907,000USD-562,000USD-902,000USD726,000USD-1,529,000USD
    Common Stock Shares Outstanding89,211,813shares78,889,000shares74,267,418shares63,758,515shares59,832,287shares47,539,631shares42,339,961shares40,433,171shares
    Non Current Assets Total166,873,000USD177,423,000USD172,138,000USD186,195,000USD193,770,000USD197,032,000USD175,735,999USD213,482,000USD
    Non Current Liabilities Total330,459,000USD334,297,000USD410,195,000USD487,571,000USD350,433,000USD303,566,000USD288,155,000USD286,286,000USD
    Non Current Liabilities Other7,601,000USD6,796,000USD8,485,000USD73,585,000USD20,379,000USD88,227,000USD83,294,000USD91,195,000USD
    Non Currrent Assets Other39,160,000USD53,818,000USD42,155,000USD59,026,000USD11,069,000USD33,489,000USD7,713,999USD-24,998,000USD
    Net Working Capital277,661,000USD215,951,000USD438,867,000USD344,274,000USD458,739,000USD317,747,000USD333,615,000USD391,057,000USD
    Unclassified Non Current Liabilities11,134,000USD17,191,000USD24,447,000USD-46,075,000USD11,118,000USD-59,891,000USD-83,294,000USD-91,195,000USD
    Unclassified Equity1,588,712,000USD1,506,306,000USD1,327,874,000USD1,059,969,000USD1,068,628,000USD797,980,000USD636,906,000USD589,791,000USD
    Good Will—753,000USD753,000USD800,000USD900,000USD936,000USD936,000USD936,000USD
    Current Deferred Revenue—2,815,000USD7,096,000USD11,976,000USD16,268,000USD-357,000USD-2,613,000USD49,695,000USD
    Short Long Term Debt—68,678,000USD—————22,457,000USD
    Unclassified Current Liabilities—-68,678,000USD—————-72,152,000USD
    Other Liab———84,516,000USD92,355,000USD59,891,000USD83,294,000USD91,195,000USD
    Net Tangible Assets———-102,187,000USD153,677,000USD57,088,000USD63,060,000USD130,626,000USD
    Unclassified Non Current Assets—————-7,814,000USD-14,709,000USD—
    Long Term Investments——————0USD15,000,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation29,446,000USD
    Stock Based Compensation37,934,000USD
    Other Non Cash Items2,614,000USD
    Change To Account Receivables-583,000USD
    Change To Inventory-3,450,000USD
    Change To Liabilities-3,130,000USD
    Change In Working Capital-25,814,000USD
    Operating Cash Flow17,705,000USD
    Net Investments-141,489,000USD
    Other Investing Activities0USD
    Unclassified Investing Cash Flow-43,249,000USD
    Investing Cash Flow-184,738,000USD
    Common Stock Issuance2,356,000USD
    Unclassified Financing Cash Flow189,365,000USD
    Financing Cash Flow191,721,000USD
    Effect Of Forex Changes On Cash12,000USD
    Change In Cash24,700,000USD
    End Cash Flow117,735,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-36,602,000USD-21,986,000USD25,706,000USD-12,755,000USD-41,226,000USD-60,268,000USD-54,752,000USD-69,652,000USD
    Depreciation25,212,000USD18,137,000USD15,788,000USD14,016,000USD12,802,000USD12,091,000USD11,239,000USD10,345,000USD
    Stock Based Compensation16,146,000USD11,464,000USD11,263,000USD10,649,000USD11,492,000USD9,214,000USD8,022,000USD9,919,000USD
    Other Non Cash Items-4,000USD397,000USD-1,108,000USD-1,289,000USD-1,569,000USD-4,158,000USD-278,000USD69,882,000USD
    Change To Account Receivables-7,225,000USD28,668,000USD-44,155,000USD-4,282,000USD-7,204,000USD-2,025,000USD-731,000USD-1,739,000USD
    Change To Inventory-742,000USD1,177,000USD194,000USD-19,000USD3,664,000USD-285,000USD-246,000USD-1,416,000USD
    Change In Working Capital-45,118,000USD52,666,000USD-37,332,000USD-5,638,000USD-23,693,000USD7,401,000USD-6,738,000USD-60,737,000USD
    Total Cash From Operating Activities-40,366,000USD60,678,000USD14,317,000USD4,983,000USD-42,194,000USD-35,720,000USD-42,507,000USD-40,243,000USD
    Capital Expenditures-22,178,000USD-18,864,000USD-140,000USD-235,000USD-11,784,000USD-9,561,000USD-8,192,000USD-11,993,000USD
    Free Cash Flow-62,544,000USD41,814,000USD14,177,000USD4,748,000USD-53,978,000USD-45,281,000USD-50,699,000USD-52,236,000USD
    Investments43,727,000USD-85,505,000USD86,591,000USD4,850,000USD41,290,000USD-80,309,000USD46,126,000USD28,610,000USD
    Total Cashflows From Investing Activities21,549,000USD-104,839,000USD86,591,000USD4,850,000USD41,290,000USD-80,309,000USD46,126,000USD28,610,000USD
    Total Cash From Financing Activities4,204,000USD26,679,000USD-65,339,000USD1,475,000USD3,718,000USD139,119,000USD46,000USD782,000USD
    Change In Cash-14,673,000USD-17,895,000USD35,776,000USD13,257,000USD3,362,000USD22,126,000USD4,118,000USD-10,960,000USD
    Begin Period Cash Flow93,035,000USD110,930,000USD75,154,000USD61,897,000USD58,535,000USD36,409,000USD32,291,000USD43,251,000USD
    End Period Cash Flow78,362,000USD93,035,000USD110,930,000USD75,154,000USD61,897,000USD58,535,000USD36,409,000USD32,291,000USD
    Other Cashflows From Investing Activities-22,178,000USD-470,000USD3,000USD-11,940,000USD-83,000USD-40,000USD-26,569,000USD-65,000,000USD
    Other Cashflows From Financing Activities-525,000USD-525,000USD-525,000USD-525,000USD-525,000USD4,381,000USD-525,000USD-525,000USD
    Unclassified Investing Cash Flow22,178,000USD——12,175,000USD11,867,000USD9,601,000USD34,761,000USD76,993,000USD
    Unclassified Financing Cash Flow4,729,000USD27,204,000USD-64,814,000USD2,000,000USD4,243,000USD——1,307,000USD
    Net Borrowings—0USD——————
    Issuance Of Capital Stock—————134,738,000USD0USD0USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income-25,546,000USD-320,630,000USD-376,333,000USD-331,468,000USD-217,292,000USD-169,431,000USD-146,427,000USD-102,678,000USD
    Depreciation60,743,000USD43,555,000USD38,530,000USD20,719,000USD12,746,000USD24,579,000USD20,408,000USD18,668,000USD
    Stock Based Compensation44,868,000USD36,913,000USD44,246,000USD38,143,000USD29,566,000USD23,614,000USD21,105,000USD19,774,000USD
    Other Non Cash Items-28,284,000USD65,707,000USD39,011,000USD85,440,000USD79,413,000USD102,543,000USD44,076,000USD7,864,000USD
    Change To Account Receivables-27,822,000USD-6,042,000USD-11,299,000USD-1,434,000USD17,952,000USD2,301,000USD-4,629,000USD152,000USD
    Change To Inventory5,016,000USD-3,771,000USD-39,420,000USD-1,209,000USD117,000USD-5,067,000USD-1,958,000USD-2,773,000USD
    Change In Working Capital-13,997,000USD-63,020,000USD-25,475,000USD875,000USD80,775,000USD-26,042,000USD2,624,000USD11,069,000USD
    Total Cash From Operating Activities37,784,000USD-237,475,000USD-280,021,000USD-186,291,000USD-14,792,000USD-42,743,000USD-58,214,000USD-24,958,000USD
    Capital Expenditures-58,157,000USD-101,212,000USD-41,591,000USD-28,366,000USD-24,151,000USD-119,845,000USD-15,565,000USD-19,701,000USD
    Free Cash Flow-20,373,000USD-338,687,000USD-321,612,000USD-214,657,000USD-38,943,000USD-162,588,000USD-73,779,000USD-44,659,000USD
    Investments86,453,000USD99,325,000USD36,025,000USD-3,396,000USD-113,472,000USD58,518,000USD35,428,000USD-183,590,000USD
    Total Cashflows From Investing Activities27,892,000USD99,325,000USD55,776,000USD-32,553,000USD-137,623,000USD-61,327,000USD19,863,000USD-203,291,000USD
    Net Borrowings-68,904,000USD0USD0USD95,044,000USD104,926,000USD104,926,000USD104,926,000USD235,797,000USD
    Total Cash From Financing Activities-33,467,000USD139,422,000USD218,752,000USD117,573,000USD231,683,000USD127,713,000USD-2,077,000USD231,863,000USD
    Issuance Of Capital Stock0USD134,738,000USD191,198,000USD19,545,000USD224,934,000USD131,520,000USD——
    Change In Cash34,500,000USD359,000USD-3,512,000USD-104,065,000USD80,981,000USD22,336,000USD-40,437,000USD3,479,000USD
    Begin Period Cash Flow58,535,000USD58,176,000USD61,688,000USD165,753,000USD84,772,000USD62,436,000USD102,873,000USD99,394,000USD
    End Period Cash Flow93,035,000USD58,535,000USD58,176,000USD61,688,000USD165,753,000USD84,772,000USD62,436,000USD102,873,000USD
    Other Cashflows From Investing Activities-404,000USD-101,252,000USD165,811,000USD-28,966,000USD-19,050,000USD-113,078,000USD-15,370,000USD-202,564,000USD
    Other Cashflows From Financing Activities-2,100,000USD4,684,000USD27,554,000USD-6,898,000USD6,749,000USD-3,807,000USD-2,077,000USD-3,934,000USD
    Unclassified Financing Cash Flow37,537,000USD——2,319,000USD117,896,000USD24,548,000USD-104,926,000USD—
    Unclassified Investing Cash Flow—202,464,000USD-104,469,000USD28,175,000USD19,050,000USD113,078,000USD15,370,000USD202,564,000USD
    Change To Liabilities———22,845,000USD22,315,000USD-6,036,000USD9,255,000USD-2,708,000USD
    Sale Purchase Of Stock———27,108,000USD2,112,000USD2,046,000USD——
    Cash And Cash Equivalents Changes———-101,271,000USD79,268,000USD23,643,000USD——
    Unclassified Operating Cash Flow—————1,994,000USD—20,345,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30ProductFILSPARI141,078,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductLicense8,232,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductTiopronin Products20,274,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductFILSPARI105,152,000USD0001438533-26-000042
    Q1 2026Quarterly · 2026-03-31ProductLicense2,707,000USD0001438533-26-000042
    Q1 2026Quarterly · 2026-03-31ProductTiopronin Products19,340,000USD0001438533-26-000042
    Q1 2025Quarterly · 2025-03-31ProductFILSPARI55,881,000USD0001438533-26-000042
    Q1 2025Quarterly · 2025-03-31ProductLicense5,871,000USD0001438533-26-000042
    Q1 2025Quarterly · 2025-03-31ProductTiopronin Products19,980,000USD0001438533-26-000042
    Q4 2024Quarterly · 2024-12-31ProductFILSPARI49,644,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductLicense1,241,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductTiopronin Products23,902,000USDLegacy provider
    FY 2024Yearly · 2024-12-31ProductFILSPARI132,222,000USD0001438533-26-000014
    FY 2024Yearly · 2024-12-31ProductLicense6,468,000USD0001438533-26-000014
    FY 2024Yearly · 2024-12-31ProductRoyalty600,000USD0001438533-26-000014
    FY 2024Yearly · 2024-12-31ProductTiopronin Products94,485,000USD0001438533-26-000014
    Q3 2024Quarterly · 2024-09-30ProductFILSPARI35,619,000USD0001438533-25-000056
    Q3 2024Quarterly · 2024-09-30ProductLicense1,897,000USD0001438533-25-000056
    Q3 2024Quarterly · 2024-09-30ProductTiopronin Products25,382,000USD0001438533-25-000056
    Q2 2024Quarterly · 2024-06-30ProductFILSPARI27,125,000USD0001438533-25-000046
    Q2 2024Quarterly · 2024-06-30ProductLicense1,940,000USD0001438533-25-000046
    Q2 2024Quarterly · 2024-06-30ProductTiopronin Products25,051,000USD0001438533-25-000046
    Q1 2024Quarterly · 2024-03-31ProductFILSPARI19,834,000USD0001438533-25-000026
    Q1 2024Quarterly · 2024-03-31ProductLicense1,390,000USD0001438533-25-000026
    Q1 2024Quarterly · 2024-03-31ProductTiopronin Products20,150,000USD0001438533-25-000026
    FY 2023Yearly · 2023-12-31ProductFILSPARI29,208,000USD0001438533-26-000014
    FY 2023Yearly · 2023-12-31ProductLicense17,701,000USD0001438533-26-000014
    FY 2023Yearly · 2023-12-31ProductRoyalty0USD0001438533-26-000014
    FY 2023Yearly · 2023-12-31ProductTiopronin Products98,329,000USD0001438533-26-000014
    Q3 2023Quarterly · 2023-09-30ProductFILSPARI8,044,000USD0001438533-23-000048
    Q3 2023Quarterly · 2023-09-30ProductLicense3,200,000USD0001438533-23-000048
    Q3 2023Quarterly · 2023-09-30ProductTiopronin Products25,888,000USD0001438533-23-000048
    FY 2022Yearly · 2022-12-31ProductFILSPARI0USD0001438533-25-000010
    FY 2022Yearly · 2022-12-31ProductLicense11,490,000USD0001438533-25-000010
    FY 2022Yearly · 2022-12-31ProductTiopronin Products97,970,000USD0001438533-25-000010
    FY 2021Yearly · 2021-12-31ProductFILSPARI0USD0001438533-24-000005
    FY 2021Yearly · 2021-12-31ProductLicense16,714,000USD0001438533-24-000005
    FY 2021Yearly · 2021-12-31ProductTiopronin Products115,122,000USD0001438533-24-000005
    FY 2020Yearly · 2020-12-31ProductBile Acid Products89,438,000USD0001438533-23-000008
    FY 2020Yearly · 2020-12-31ProductLicense0USD0001438533-23-000008
    FY 2020Yearly · 2020-12-31ProductTiopronin Products108,883,000USD0001438533-23-000008
    FY 2019Yearly · 2019-12-31ProductBile Acid Products79,700,000USD0001438533-22-000008
    FY 2019Yearly · 2019-12-31ProductLicense0USD0001438533-22-000008
    FY 2019Yearly · 2019-12-31ProductTiopronin Products95,638,000USD0001438533-22-000008
    FY 2018Yearly · 2018-12-31ProductBile Acid Products75,070,000USD0001438533-21-000008
    FY 2018Yearly · 2018-12-31ProductTiopronin Products89,176,000USD0001438533-21-000008
    FY 2017Yearly · 2017-12-31ProductBile Acid Products72,626,000USD0001438533-20-000004
    FY 2017Yearly · 2017-12-31ProductThiola License82,311,000USD0001438533-20-000004

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.